Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (25)

2024

  1. Repetitive ambulatory levosimendan as a bridge to heart transplantation

    Revista Espanola de Cardiologia, Vol. 77, Núm. 4, pp. 290-301

2023

  1. Twenty-four hour ambulatory blood pressure monitoring in patients with stable heart failure. Prevalence and associated factors

    Revista Espanola de Cardiologia, Vol. 76, Núm. 11, pp. 852-861

  2. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial

    European Journal of Heart Failure, Vol. 25, Núm. 3, pp. 373-385

2022

  1. Dose of furosemide before admission predicts diuretic efficiency and long-term prognosis in acute heart failure

    ESC Heart Failure, Vol. 9, Núm. 1, pp. 656-666

  2. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure

    Frontiers in Cardiovascular Medicine, Vol. 9

  3. Utility of the IMPACT score for predicting heart transplant mortality. Analysis on a contemporary cohort of the Spanish Heart Transplant Registry

    Clinical Transplantation, Vol. 36, Núm. 9

2021

  1. Modes of death in heart failure according to age, sex and left ventricular ejection fraction

    Internal and Emergency Medicine, Vol. 16, Núm. 3, pp. 643-652

  2. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

    Frontiers in Cardiovascular Medicine, Vol. 8

2020

  1. Changes in causes of death and influence of therapeutic improvement over time in patients with heart failure and reduced ejection fraction

    Revista Espanola de Cardiologia, Vol. 73, Núm. 7, pp. 561-568

  2. Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

    JACC: Basic to Translational Science, Vol. 5, Núm. 4, pp. 317-327

  3. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain

    Revista Espanola de Cardiologia, Vol. 73, Núm. 5, pp. 361-367

  4. Estimated population prevalence of heart failure with reduced ejection fraction in spain, according to dapa-hf study criteria

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-15

  5. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

  6. The development of chronic diuretic resistance can be predicted during a heartfailure hospitalization. Results from the REDIHF registry

    PLoS ONE, Vol. 15, Núm. 10 October

2019

  1. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure

    Current Heart Failure Reports, Vol. 16, Núm. 6, pp. 304-314

2018

  1. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial

    European Journal of Heart Failure, Vol. 20, Núm. 7, pp. 1128-1136

  2. Influence of sex and pregnancy on survival in patients admitted with heart failure: Data from a prospective multicenter registry

    Clinical Cardiology, Vol. 41, Núm. 7, pp. 924-930

  3. Prevalence and incidence of hyperkalaemia in the Spanish population with heart failure with reduced ejection fraction: a systematic review and populational relevance

    Revista Clinica Espanola

2017

  1. La fracción de eyección intermedia no permite estratificar el riesgo de los pacientes hospitalizados por insuficiencia cardiaca

    Revista Espanola de Cardiologia, Vol. 70, Núm. 5, pp. 338-346

  2. Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failure

    International Journal of Cardiology, Vol. 240, pp. 265-270